Alzheimer’s Disease | Special Topics | US | 2022
In June 2021, Biogen / Eisai’s anti-Aβ MAb Aduhelm received accelerated approval from the FDA for the treatment of Alzheimer’s disease (AD), making it the first potential DMT approved for this devastating disease. While Aduhelm’s launch has been met with controversy and its use curtailed by lack of CMS coverage, the potential for full / traditional approval of others in the class (including agents from Eisai / Biogen, Eli Lilly, and Novo Nordisk) could introduce a radically new era in disease management in the coming years. Meanwhile, new symptomatic agents for cognition (Corium’s Adlarity) and AD agitation (Lundbeck / Otsuka’s Rexulti, Avanir / Otsuka’s AVP-786, Axsome’s AXS-05, BioXcel’s BXCL-501) will introduce new choices in areas of unmet need. As the AD therapy market evolves to include increased treatment choice and complexity, understanding how prescribers perceive and plan to incorporate new brands in the AD treatment paradigm is critical. Recognizing the critical role that cost and coverage will play in the access and uptake of new, premium-priced options, this report also aims to provide additional perspective from U.S. payers.
Questions answered
- How do specialists and nonspecialists view the clinical profiles and areas of differentiation among recently approved therapies and emerging DMTs?
- How will physicians incorporate emerging DMTs into the treatment algorithm? What factors will drive or constrain their use?
- What factors will drive or constrain the prescribing of new adjunctive therapies for neuropsychiatric symptoms of AD? How will these drugs compete with off-label generic alternatives?
- How do payers view the clinical profiles of pipeline therapies? What are the value drivers that will influence formulary decisions? What restrictions / requirements do payers envision?
Product description
Clarivate’s Special Topics reports use quantitative and/or qualitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report will help developers gauge the competitiveness and sales potential of late-phase assets in the AD market.
